Donna Kinzler
Acute Care · Pittsburgh, PANPI 1770783383
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $16,308 of the $25,255 with a category attached, or 64.6%. 12 manufacturers reported payments, led by GSK at 44.3% of the total. Reporting peaked in 2023 at $10,345 and has fallen 93.0% since, to $720 in 2025. Among acute care clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 71 payments — averaging $355.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$11K
- Merck$9K
- AbbVie$2K
- AstraZeneca$991
- E.r. Squibb & Sons, L.L.C.$625
- Eisai Inc.$365
- plus $830 from 6 others
What the payments were for
- Consulting fees$1,5386%
- Speaking & faculty fees$16,30865%
- Travel & lodging$3,05412%
- Food & beverage$4,29317%
- Education$620%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 16 | $11,197 |
| Merck | 21 | $9,322 |
| AbbVie | 6 | $1,926 |
| AstraZeneca | 11 | $991 |
| E.r. Squibb & Sons, L.L.C. | 4 | $625 |
| Eisai Inc. | 5 | $365 |
| Genmab U.S., Inc. | 3 | $334 |
| Pfizer | 1 | $150 |
| Incyte Corporation | 1 | $129 |
| Myriad Genetic Laboratories, Inc. | 1 | $108 |
| Blueprint Medicines Corporation | 1 | $96 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,255 in reported general payments places this provider in the 95th percentile of 872 acute care providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 12 | $356 |
| Pantoprazole Sodium | 16 | $326 |
| Dexamethasone | 25 | $179 |
| Gabapentin | 14 | $131 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 11 | $113 |
| Prednisone | 12 | $57 |
| Oxycodone Hcl | 11 | $44 |
Paid to pharmacies, not to this prescriber.
Other acute care in Pittsburgh
- Jamie VarleyPittsburgh$7K
- Kristi MontrellaAltoona$111K
- Kathryn GreenPhiladelphia$92K
- Caroline PratzPhiladelphia$77K
- Lisa JohnsonPottstown$25K
- Kathryn McParlaneMoon Township$21K
- Rebecca MarcantuonoPhiladelphia$17K
- Stephanie TothPhiladelphia$17K
- Kevin HaganAbington$17K
- Rachel ChristyButler$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.